Brian Weinstein expressed concern about competition in the HPV space and a stock that has tracked the overall market since 2007, but gave a thumbs up to the $355 acquisition of Cellestis.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.